TY - JOUR T1 - Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - S20 LP - S25 DO - 10.1097/IGC.0000000000000289 VL - 24 IS - Supp 3 AU - Aikou Okamoto AU - Rosalind M. Glasspool AU - Seiji Mabuchi AU - Noriomi Matsumura AU - Hiroyuki Nomura AU - Hiroaki Itamochi AU - Masashi Takano AU - Tadao Takano AU - Nobuyuki Susumu AU - Daisuke Aoki AU - Ikuo Konishi AU - Alan Covens AU - Jonathan Ledermann AU - Delia Mezzazanica AU - Christopher Steer AU - David Millan AU - Iain A. McNeish AU - Jacobus Pfisterer AU - Sokbom Kang AU - Laurence Gladieff AU - Jane Bryce AU - Amit Oza Y1 - 2014/11/01 UR - http://ijgc.bmj.com/content/24/Supp_3/S20.abstract N2 - Abstract Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than high-grade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration. ER -